Use of serum SDF-1 as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Basik, M
  • Aguilar-Mahecha, A
  • Chapman, JW
  • Jahan, K
  • Hassan, S
  • Han, L
  • Wilson, CF
  • Pritchard, Kathleen
  • Shepherd, LE
  • Pollak, MN

publication date

  • May 20, 2010